ArticleOncotarget2017

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

Natasha B Leighl et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.